111 results about "Neuraminidase" patented technology

The invention discloses a neuraminidase-targeted drug-loaded nanoparticle as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. Polysialic acid and poly (lactic-co-glycolic acid) are connected through ester bond connection to obtain the drug-loaded nanoparticles with stable structure and performance, and the drug-loaded nanoparticles have the effect of targeting neuraminidase and also have high efficiency of entering cells; the antibiotic drug is further dispersed in the drug-loaded nanoparticles, the inflammation regulating agent is adsorbed on the surface of the drug-loaded nanoparticles, and the drug-loaded nanoparticles can deliver the antibiotic drug and the inflammation regulating agent to the pig Gleisseria in the pig body. According to the present invention, the antibiotic drug and the inflammation regulating agent are released under the acidic environment at the infection site in the pig body, such that the pig Gleisseria is efficiently killed, the inflammation damage caused by bacterial infection and the toxic damage of the antibiotic drug are reduced, and the good application prospect is provided in the preparation of the drug for preventing and / or treating the pig Gleisseria infection.

The present invention provides vectors and / or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and / or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.

The invention discloses an anti-neuraminidase human monoclonal antibody obtained through multiple rounds of in-vitro screening and recombination transformation and application of the anti-neuraminidase human monoclonal antibody. The application refers to preparation of products for preventing, detecting or treating influenza viruses. The monoclonal antibody provided by the invention has remarkable neuraminidase inhibitory activity and broad-spectrum influenza virus antigen binding capacity, has excellent prevention and treatment effects on various seasonal influenza viruses, provides a new technical choice for resisting influenza infection, and has important application value.

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

The invention discloses a preparation method of an electrochemical biosensor based on neuraminidase, and relates to the field of electrochemical sensors. The method comprises the following steps: preparing N-Gr / MWCNTs, preparing N-Gr / MWCNTs (at) GCE, preparing Ppy / N-Gr / MWCNTs (at) GCE, and preparing NA / Ppy / N-Gr / MWCNTs (at) GCE. According to the electrochemical biosensor based on neuraminidase, MWCNTs and N-Gr are compounded to form an N-Gr / MWCNTs composite material, high-conductivity polypyrrole is polymerized on the N-Gr / MWCNTs composite material through pyrrole, the biosensor without a mediator is prepared, electrons can be directly transmitted between an electrode and a bioactive substance, and the electrochemical biosensor can be used for detecting neuraminidase. The response performance of the sensor is obviously improved; the electrochemical biosensor is based on the NA inhibition principle, is mainly used for rapidly screening antiviral components in traditional Chinese medicines, can realize rapid screening and evaluation of the antiviral components in the traditional Chinese medicines, belongs to a convenient, efficient and low-cost means, and also provides scientific basis and technical support for discovery and evaluation of active components.

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

The invention provides an application of bortezomib in preparation of an anti-avian influenza virus drug. The bortezomib has the application of inhibiting the activity of avian influenza virus H7N9 neuraminidase. Researches show that the bortezomib can be combined with neuraminidase, the virtual calculation activity IC50 based on calculation is 3.37 * 10 <-7 > mol / L, the bortezomib can reduce the activity of neuraminidase, and the IC50 is 35.561 mu M; the bortezomib can inhibit the replication and propagation of avian influenza H7N9, and the IC50 is 0.043 [mu] M. In a word, the bortezomib has obvious activity of inhibiting neuraminidase of the avian influenza virus H7N9 and has the application of resisting the avian influenza virus.

To disclose modified influenza virus neuraminidases that improve viral replication, thus improving the yield of vaccine viruses.SOLUTION: Expression of such modified neuraminidases by influenza virus stabilizes co-expressed hemagglutinins, ensuring that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.SELECTED DRAWING: None

The present invention discloses drug-loaded nanoparticles targeting neuraminidase, as well as a preparation method and application thereof, belonging to the technical field of pharmaceutical preparations. The present invention connects polysialic acid and polylactic acid glycolic acid via an ester bond to obtain drug-loaded nanoparticles with stable structure and performance. The drug-loaded nanoparticles have the function of targeting neuraminidase and have relatively high efficiency in entering cells. Furthermore, antibiotics are dispersed in the drug-loaded nanoparticles, and an inflammatory modulator is adsorbed on the surface of the drug-loaded nanoparticles. The drug-loaded nanoparticles can deliver the antibiotics and the inflammatory modulator to Grasseria suis in pigs, releasing the antibiotics and the inflammatory modulator in the slightly acidic environment of the infected site in the pig, thereby efficiently killing Grasseria suis and reducing inflammatory damage caused by bacterial infection and toxic damage of the antibiotics. Therefore, the present invention has good application prospects in the preparation of drugs for preventing and / or treating Grasseria suis infection.

In one aspect, provided herein are immunogenic compositions comprising CpG oligonucleotide adjuvant, and a recombinant neuraminidase, wherein the recombinant neuraminidase comprises a globular head domain of influenza virus neuraminidase and a tetramerization domain, and wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions.

Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

The present invention relates to the technical field of natural drug chemistry, and specifically discloses a rose extract, a preparation method thereof, and an application thereof in the preparation of a drug having a neuraminidase inhibitory effect. The preparation method of the rose extract comprises the following steps: taking roses, then extracting with ethanol, concentrating and drying the extract after the extraction is completed to obtain a rose ethanol extract, that is, the rose extract. Studies have shown that the rose extract prepared by the method of the present invention has an excellent neuraminidase inhibitory effect; its inhibitory effect on neuraminidase is significantly higher than that of oseltamivir carboxylate. Therefore, the rose extract of the present invention is used as an effective ingredient to prepare a drug having a neuraminidase inhibitory effect, which has important application value.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a Nucleozin dimer derivative as well as a preparation method and application thereof. The Nucleozin dimer derivative provided by the invention has relatively good anti-influenza virus activity, can remarkably inhibit the enzyme activity of virus neuraminidase so as to play the anti-influenza virus activity, and has relatively good targeting selectivity and relatively low cytotoxicity. The Nucleozin dimer derivative disclosed by the invention can be applied to preparation of an anti-influenza virus drug or preparation of a neuraminidase inhibitor.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

In one aspect, provided herein are immunogenic compositions comprising CpG oligonucleotide adjuvant, and a recombinant neuraminidase, wherein the recombinant neuraminidase comprises a globular head domain of influenza virus neuraminidase and a tetramerization domain, and wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions.

This invention relates to retroviral gene transfer vectors, particularly lentiviral vectors, pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).

The invention relates to antigen-binding polypeptides specifically binding neuraminidase and / or haemagglutinin protein from Influenza B virus resulting in broadly neutralizing IBV antigen-binding polypeptides or antibodies. More specifically the invention relates to immunoglobulin single variable domains specifically binding NA or HA, which upon fusion to bispecific antigen-binding proteins provide for a broader and improved neutralization capacity as compared to a combination of IBV NA- and HA- targeting ISVDs or antibodies. The invention further relates to the use of said antigen-binding proteins for medical purposes, more specifically in prophylactic or therapeutic treatment of a subject, even more specifically to prevent or treat IBV infections.

Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The present disclosure relates to a cluster-based consensus method for producing recombinant neuraminidase (NA) polypeptides. The present disclosure further relates to influenza vaccine compositions comprising the recombinant NA polypeptides.

To provide influenza mutations that inhibit the acquisition of antigenicity-compromising mutations in a hemagglutinin (HA) segment of influenza virus during growth in eggs.SOLUTION: Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.SELECTED DRAWING: Figure 12

The present invention belongs to the field of biomedicine, and specifically relates to an extraction method and application of an active ingredient of Shengjiang Powder that inhibits neuraminidase. The extraction method comprises the following steps: (1) preparing a crude extract of Shengjiang Powder: taking silkworm pupa, cicada shell, rhubarb, and turmeric, adding water, heating under reflux for extraction, filtering, concentrating, cooling, adding anhydrous ethanol, filtering, and concentrating to dryness to obtain a crude extract of Shengjiang Powder; (2) extracting the crude extract of Shengjiang Powder with a three-phase extraction solvent, collecting the upper phase, middle phase, and lower phase respectively, repeating the extraction 5 times, concentrating and drying to obtain extracts of each part; (3) subjecting the middle phase extract to high-speed countercurrent chromatography, using an eluent for primary separation and secondary separation according to the elution procedure, and automatically collecting the fractions; (4) concentrating and drying to obtain the active ingredient. The extracted active ingredient is applied to the preparation of a drug that inhibits neuraminidase, providing a basis for the development of such drugs.

The present invention relates to an in-vitro transduction enhancer and a method for detecting infection efficacy, and particularly, provided is an in-vitro transduction enhancer which comprises one or more of neuraminidase (NA), sodium butyrate (NaBu) and Poly-Lysine. It is found for the first time that the enhancer can greatly reduce a usage amount of viruses or vectors (such as viral vectors) and has a better efficacy detection effect, so that a technical bottleneck is broken through, and a technical obstacle in the art is solved.

The present invention relates to a retroviral vector, in particular a lentiviral vector, comprising a modified retroviral RNA sequence substituted with a codon and comprising a reduced number of retroviral open reading frames, a method for the production thereof, and uses thereof, and wherein the retroviral vector is pseudo-modeled by hemagglutinin-neuraminidase (HN) and fusion (F) proteins from respiratory paramyxovirus.

Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

Provided are a modified-type neuraminidase, a gene encoding the modified-type neuraminidase, a combination of the modified-type neuraminidase and cathepsin A, a combination of the gene encoding the modified-type neuraminidase and a gene encoding cathepsin A, a vector including said genes, and a pharmaceutical composition containing same. The pharmaceutical composition can be used for the therapy of lysosomal storage disease.

An influenza virus neuraminidase (NA) active site proximity assay (NASPA) for detecting and / or quantifying NAI antibodies in biological samples is described. NASPA can also be used, for example, to evaluate NA antigenicity and profile anti-NA antibody responses in humans and non-human animals. NASPA is based on the ability to detect the binding of a large NA active site inhibitor in the presence of anti-NA antibodies with a small reporter substrate. The assay is performed by sequentially adding test sera to a defined amount of NA (or influenza virus containing NA), followed by addition of the NA active site inhibitor and then the small substrate for measuring NA activity. In view of the flexibility of the modular approach and the ease of automation, the disclosed methods can be used to efficiently collect NA antigenic data and profile complex anti-NA antibody responses.

The present invention provides compositions comprising one or more polynucleotides that encode a neuraminidase (NA) polypeptide and a hemagglutinin (HA) polypeptide separated by a furin cleavage site and a self-cleaving 2A polypeptide. Methods of using these compositions to induce an immune response to influenza in a subject are also provided.